Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study
Ionut Bebu, David Schade, Barbara Braffett, Mikhail Kosiborod, Maria Lopes-Virella, Elsayed Z Soliman, William H Herman, David A Bluemke, Amisha Wallia, Trevor Orchard, John M Lachin, DCCT/EDIC Research Group, Ionut Bebu, David Schade, Barbara Braffett, Mikhail Kosiborod, Maria Lopes-Virella, Elsayed Z Soliman, William H Herman, David A Bluemke, Amisha Wallia, Trevor Orchard, John M Lachin, DCCT/EDIC Research Group
Abstract
Objective: The Diabetes Control and Complications Trial (DCCT) and its observational follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) demonstrated the dominant role of glycemia, second only to age, as a risk factor for a first cardiovascular event in type 1 diabetes (T1D). We now investigate the association between established risk factors and the total cardiovascular disease (CVD) burden, including subsequent (i.e., recurrent) events.
Research design and methods: CVD events in the 1,441 DCCT/EDIC participants were analyzed separately by type (CVD death, acute myocardial infarction [MI], stroke, silent MI, angina, percutaneous transluminal coronary angioplasty/coronary artery bypass graft [PTCA/CABG], and congestive heart failure [CHF]) or as composite outcomes (CVD or major adverse cardiovascular events [MACE]). Proportional rate models and conditional models assessed associations between risk factors and CVD outcomes.
Results: Over a median follow-up of 29 years, 239 participants had 421 CVD events, and 120 individuals had 149 MACE. Age was the strongest risk factor for acute MI, silent MI, stroke, and PTCA/CABG, while glycemia was the strongest risk factor for CVD death, CHF, and angina, second strongest for acute MI and PTCA/CABG, third strongest for stroke, and not associated with silent MI. HbA1c was the strongest modifiable risk factor for a first CVD event (CVD: HR 1.38 [95% CI 1.21, 1.56] per 1% higher HbA1c; MACE: HR 1.54 [1.30, 1.82]) and also for subsequent CVD events (CVD: incidence ratio [IR] 1.28 [95% CI 1.09, 1.51]; MACE: IR 1.89 [1.36, 2.61]).
Conclusions: Intensive glycemic management is recommended to lower the risk of initial CVD events in T1D. After a first event, optimal glycemic control may reduce the risk of recurrent CVD events and should be maintained.
Trial registration: ClinicalTrials.gov NCT00360893 NCT00360815.
© 2020 by the American Diabetes Association.
Figures
References
- Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006;29:2528–2538
- Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006;29:798–804
- Livingstone SJ, Looker HC, Hothersall EJ, et al. . Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 2012;9:e1001321.
- de Ferranti SD, de Boer IH, Fonseca V, et al. . Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014;37:2843–2863
- Nathan DM, Cleary PA, Backlund JY, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group Risk factors for cardiovascular disease in type 1 diabetes. Diabetes 2016;65:1370–1379
- Bebu I, Braffett BH, Pop-Busui R, Orchard TJ, Nathan DM, Lachin JM; DCCT/EDIC Research Group . The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. Diabetologia 2017;60:2084–2091
- Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM; DCCT/EDIC Research Group . Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC Study. Diabetes Care 2019;42:1284–1289
- The DCCT Research Group The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530–545
- The DCCT/EDIC Research Group Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111
- Writing Group for the DCCT/EDIC Research Group Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 2016;39:1621–1630
- Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New-York, Springer-Verlag, 2000
- Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 2005;96:3K–13K; discussion 34K–35K
- Miller RG, Mahajan HD, Costacou T, Sekikawa A, Anderson SJ, Orchard TJ. A contemporary estimate of total mortality and cardiovascular disease risk in young adults with type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2016;39:2296–2303
- van der Heijden AA, Van’t Riet E, Bot SD, et al. . Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes Care 2013;36:3498–3502
- Giorda CB, Avogaro A, Maggini M, et al. .; Diabetes and Informatics Study Group . Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care 2008;31:2154–2159
- Laing SP, Swerdlow AJ, Slater SD, et al. . The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16:466–471
- Poirier P, Bertrand OF, Leipsic J, Mancini GBJ, Raggi P, Roussin A; Diabetes Canada Clinical Practice Guidelines Expert Committee . Screening for the presence of cardiovascular disease. Can J Diabetes 2018;42(Suppl. 1):S170–S177
- Pop-Busui R, Low PA, Waberski BH, et al. .; DCCT/EDIC Research Group . Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009;119:2886–2893
- Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in type 1 diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) study: a comparison with the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Diabetes 2019;68:409–419
Source: PubMed